Results 311 to 320 of about 365,877 (337)
Some of the next articles are maybe not open access.
Assessing Toripalimab in NSCLC
Cancer Discovery, 2022Abstract According to CHOICE-01, a phase III trial in China, the PD-1 inhibitor toripalimab plus chemotherapy improves progression-free survival in patients with untreated non–small cell lung cancer lacking actionable mutations. The findings boost combination chemo–immunotherapy, rather than chemotherapy alone, as the new standard for ...
openaire +2 more sources
Multimodality Therapy for NSCLC
2016The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains ...
Lingling, Du +2 more
openaire +2 more sources
Journal of Clinical Oncology, 2014
e18516 Background: Lung cancer has a poor prognosis, with 15-20% five-years survival rate. However, lung cancer treatment has in the last years taken advantage of newly developed targeted therapies...
Åslaug Helland +9 more
openaire +1 more source
e18516 Background: Lung cancer has a poor prognosis, with 15-20% five-years survival rate. However, lung cancer treatment has in the last years taken advantage of newly developed targeted therapies...
Åslaug Helland +9 more
openaire +1 more source
Durvalumab Promising for NSCLC
Cancer Discovery, 2017Abstract The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non–small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States
openaire +2 more sources